P2u purinoceptor modulation of intracellular Ca2+ in a human lung adenocarcinoma cell line: down-regulation of Ca2+ influx by protein kinase C

Cell Calcium. 1996 Oct;20(4):339-46. doi: 10.1016/s0143-4160(96)90039-1.

Abstract

The human lung small cell adenocarcinoma cell line, A549, demonstrates a concentration-dependent rise in [Ca2+]i in response to extracellular nucleotides. The cells show Ca2+ mobilization on addition of various nucleotides, with an order of agonist potency: UTP > or = ATP > ADP > ADP beta S > AMP; adenosine is ineffective. The EC50 values for UTP and ATP are 12.5 +/- 0.4 microM and 18.9 +/- 0.5 microM, respectively. Together, these results are strongly indicative of the P2U subclass being the major nucleotide receptor expressed in these cells. The Ca2+ response was typically biphasic consisting of an initial spike, representing release of Ca2+ from internal stores, and a subsequent plateau representing Ca2+ influx. The majority of cells showed an agonist-induced Ca2+ increase that was unaffected by pretreatment with the Ca(2+)-ATPase inhibitors 2,5-di(tert-butyl)1,4-benzohydroquinone or thapsigargin. Caffeine did not raise [Ca2+]i above basal levels and applied in conjunction with nucleotide did not attenuate the agonist-mediated response. The Ca2+ influx was sensitive to protein kinase C, and agonist addition in the presence of a protein kinase C inhibitor, D-erythrosphingosine, produced a significantly potentiated Ca2+ influx. Furthermore, agonist-mediated Ca2+ influx was abolished in the presence of a protein kinase C activator, phorbol 12,13-dibutyrate. It is concluded that these cells posses a functional P2U receptor that, upon activation, causes Ca2+ mobilization from TBQ and thapsigargin insensitive stores followed by protein kinase C regulated Ca2+ influx.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma
  • Adenosine Diphosphate / analogs & derivatives
  • Adenosine Diphosphate / pharmacology
  • Adenosine Monophosphate / pharmacology
  • Adenosine Triphosphate / pharmacology
  • Benzoquinones / pharmacology
  • Caffeine / pharmacology
  • Calcium / metabolism*
  • Down-Regulation / physiology*
  • Enzyme Inhibitors / pharmacology
  • Humans
  • Lung Neoplasms
  • Phosphodiesterase Inhibitors / pharmacology
  • Protein Kinase C / metabolism*
  • Purinergic P2 Receptor Agonists
  • Receptors, Purinergic P2 / physiology*
  • Thapsigargin / pharmacology
  • Thionucleotides / pharmacology
  • Tumor Cells, Cultured / chemistry
  • Tumor Cells, Cultured / enzymology
  • Uridine Triphosphate / pharmacology

Substances

  • Benzoquinones
  • Enzyme Inhibitors
  • Phosphodiesterase Inhibitors
  • Purinergic P2 Receptor Agonists
  • Receptors, Purinergic P2
  • Thionucleotides
  • 2,5-di-tert-butylbenzoquinone
  • adenosine 5'-O-(2-thiodiphosphate)
  • Caffeine
  • Adenosine Monophosphate
  • Adenosine Diphosphate
  • Thapsigargin
  • Adenosine Triphosphate
  • Protein Kinase C
  • Calcium
  • Uridine Triphosphate